Cardiovascular Disease Risk Prediction in Patients With Metabolic Dysfunction‐Associated Steatohepatitis
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70687 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Joe Hollinghurst und 5 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics and Outcomes Research Ltd, Cardiff, UK. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Non-alcoholic Fatty Liver Disease, Fatty Liver, Metabolic Diseases. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk.
Abstract (Originalsprache)
Background and Aims Metabolic dysfunction‐associated steatohepatitis (MASH) is associated with an increased risk of cardiovascular disease (CVD) morbidity and mortality. This study aimed to develop the first prediction models for CVD risk in a cohort of patients with MASH.
Methods
This was a retrospective cohort study using data from the UK Clinical Practice Research Datalink (CPRD) database. Accelerated failure time (AFT) models were used to predict CVD risk independently for males and females with MASH. Covariables from the QRisk3 algorithm were included: age, deprivation, body mass index, cholesterol ratio, systolic blood pressure, ethnicity, smoking status, CVD family history, diabetes, treated hypertension, rheumatoid arthritis, atrial fibrillation, chronic kidney disease (CKD), migraine, corticosteroids, anti‐psychotic medication, serious mental illness and erectile dysfunction. Measures of calibration and discrimination were determined. Observed and predicted risks were used to compare the AFT models with the QRisk3 algorithm.
Results
Utilising a cohort of 10 461 patients with MASH (5364 female and 5097 male) models to predict time to CVD were developed with moderate predictive power (C‐statistics 0.7–0.72) identifying age, cholesterol ratio, type 2 diabetes and CKD as risk factors that decrease time to CVD. Comparing the observed and predicted CV risks indicated the AFT models more accurately predicted CVD risk than the QRisk3 algorithm in patients with MASH.
Conclusions
We describe a first‐in‐kind predictive model to assess the risk of CVD in patients with MASH, which has the potential to more accurately inform the treatment and management of this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Health Economics and Outcomes Research Ltd, Cardiff, UK.
- Novo Nordisk, Gatwick, UK.
ORCID-Profile: Joe Hollinghurst
Förderung
- Novo Nordisk
Zitieren
APA
Hollinghurst, J., Augusto, M., Tefos, F., Bauer, R., Vadapalle, S., & Cardél, L. G. (2026). Cardiovascular Disease Risk Prediction in Patients With Metabolic Dysfunction‐Associated Steatohepatitis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70687
Vancouver
Hollinghurst J, Augusto M, Tefos F, Bauer R, Vadapalle S, Cardél LG. Cardiovascular Disease Risk Prediction in Patients With Metabolic Dysfunction‐Associated Steatohepatitis. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70687
BibTeX
@article{Hollinghurst2026,
author = {Hollinghurst, Joe and Augusto, Margarida and Tefos, Fotis and Bauer, Robert and Vadapalle, Sreelatha and Cardél, Lise Gehrt},
title = {Cardiovascular Disease Risk Prediction in Patients With Metabolic Dysfunction‐Associated Steatohepatitis},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70687}
}
EUVIMED